DRRX DURECT: Nilai bisnis marang pendapatan

Simbol resmi perusahaan DURECT Corporation (DRRX)

Geopolitical risks and sanctions complicate international patent protection and the supply of rare components for DURECT Corporation (DRRX). The company's price-to-sales ratio visualizes these fluctuations, where is the current value of the metric. Profit potential is based on insurance payouts for hepatitis therapy, although the clinical trial stage of epigenetic agents is temporarily increasing operating expenses.

DURECT (DRRX): Multiplikator EV/Sales saka 04.07.2022 nganti 20.11.2026

Rincian metrik keuangan lan pasar DURECT (DRRX)

- kuotasi saiki lan rata-rata prakiraan nilai:
- data kapitalisasi saham perusahaan:
Pambiji fundamental perusahaan:DURECT Corporation
Produk sing diprodhuksi durect.com

Investors must determine the objective market value of an asset by eliminating the distorting effect of debt load on capitalization. The EV/Sales metric for DURECT Corporation (DRRX) compares the total enterprise value with its annual revenue, allowing for an assessment of revenue generation efficiency, which is critical for DURECT Corporation (DRRX) given the high cost of developing patent-protected molecules for liver therapy and stringent FDA regulatory barriers.